1 of 2
Disease Overview
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. In 2004, it was the fourth most common cause of death in the world, and it is projected to be the third most common cause of death by 2030. COPD is characterized by diminished lung function, and is often accompanied by respiratory symptoms including chronic productive cough, wheezing, and dyspnea (shortness of breath). The most prominent risk factor for COPD worldwide is cigarette smoking. COPD is more common in men and the elderly, driven by long-term exposure to risk factors and the irreversible progression of COPD over time.
Market Snapshot
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. In 2004, it was the fourth most common cause of death in the world, and it is projected to be the third most common cause of death by 2030. COPD is characterized by diminished lung function, and is often accompanied by respiratory symptoms including chronic productive cough, wheezing, and dyspnea (shortness of breath). The most prominent risk factor for COPD worldwide is cigarette smoking. COPD is more common in men and the elderly, driven by long-term exposure to risk factors and the irreversible progression of COPD over time.
Market Snapshot
- The COPD market will continue to grow due to the success of combination therapies.
- Significant unmet need remains for novel therapies that prevent COPD disease progression in addition to providing symptomatic improvement.
- An increase in the total COPD population is predicted in all included markets due to aging populations.
- Paleontologists excited about the arrival of triple therapies as they will simplify disease management.
- AstraZeneca’s triple therapy PT010 will strengthen its franchise, allowing it to offer a comprehensive treatment option.
- Payers are likely to demand favorable pricing for new combination LABA/LAMAs and triple combination ICS/LABA/LAMA inhalers.
Note: Product cover images may vary from those shown
2 of 2
FORECAST: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (Published on 31 July 2018)
Overview
Recent Forecast Updates
Market Dynamics
Forecast And Future Trends
Market Definition And Methodology
Primary Research Methodology
Bibliography
Product Profile: Advair
Product Profile: Anoro Ellipta
Product Profile: Arcapta Neohaler
Product Profile: Bevespi Aerosphere
Product Profile: Breo Ellipta
Product Profile: Daliresp
Product Profile: Duaklir Pressair
Product Profile: Incruse Ellipta
Product Profile (Late Stage): Pt010
Product Profile: Seebri Neohaler
Product Profile: Spiriva
Product Profile: Stiolto Respimat
Product Profile: Striverdi Respimat
Product Profile: Symbicort
Product Profile: Trelegy Ellipta
Product Profile: Trimbow
Product Profile: Tudorza Pressair
Product Profile: Utibron Neohaler
TREATMENT: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (Published on 31 July 2018)
Overview
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends
Unmet Needs In Chronic Obstructive Pulmonary Disease
Pipeline Drugs And Future Treatment
EPIDEMIOLOGY: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (Published on 22 January 2019)
Overview
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources
MARKETED DRUGS: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (Published on 31 July 2018)
Overview
Product Overview
Product Profile: Advair
Product Profile: Anoro Ellipta
Product Profile: Arcapta Neohaler
Product Profile: Bevespi Aerosphere
Product Profile: Breo Ellipta
Product Profile: Daliresp
Product Profile: Duaklir Pressair
Product Profile: Incruse Ellipta
Product Profile: Seebri Neohaler
Product Profile: Spiriva
Product Profile: Stiolto Respimat
Product Profile: Striverdi Respimat
Product Profile: Symbicort
Product Profile: Trelegy Ellipta
Product Profile: Trimbow
Product Profile: Tudorza Pressair
Product Profile: Utibron Neohaler
COPD PRICING, REIMBURSEMENT, AND ACCESS (Published on 11 May 2016)
Overview
Executive Summary
Market Context
Global Payer And Key Opinion Leader Insights
Us Pricing
Us Payer Insights
Us Reimbursement
Japan
Five Major Eu Markets Pricing
Five Major Eu Markets Payer Insights
Generic Ics/Laba Inhalers In The Five Major Eu Markets
France
Germany
Italy
Spain
Uk
Methodology
PIPELINE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (Published on 31 July 2018)
Overview
Clinical Pipeline Overview
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Nucala
Product Profile (Late Stage): Pt010
Product Profile (Late Stage): Revefenacin
LIST OF FIGURES
Figure 1: COPD – current and future market dynamics analysis
Figure 2: The authors assessment summary of key marketed and pipeline drugs for COPD
Figure 3: COPD sales across the US, Japan, and five major EU markets, by country, 2017–26
Figure 4: Sales of Anoro Ellipta, Bevespi Aerosphere, Duaklir Pressair, Stiolto Respimat, and Utibron Neohaler across the US, Japan, and five major EU markets, 2017–26
Figure 5: Sales of Trelegy Ellipta, Trimbow, and PT010 across the US, Japan, and five major EU markets, 2017–26
Figure 6: Sales of the ICS/LABA class across the US, Japan, and five major EU markets, by product, 2017–26
Figure 7: Patient-based forecast methodology for COPD
Figure 8: Price sources and calculations, by country
Figure 9: Advair for COPD – SWOT analysis
Figure 10: The authors drug assessment summary of Advair for COPD
Figure 11: The authors drug assessment summary of Advair for COPD
Figure 12: Advair sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 13: Anoro for COPD – SWOT analysis
Figure 14: The authors drug assessment summary of Anoro for COPD
Figure 15: The authors drug assessment summary of Anoro for COPD
Figure 16: Anoro sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 17: Arcapta for COPD – SWOT analysis
Figure 18: The authors drug assessment summary of Arcapta for COPD
Figure 19: The authors drug assessment summary of Arcapta for COPD
Figure 20: Arcapta Neohaler sales for COPD across Japan and the five major EU markets, by country, 2017–26
Figure 21: Bevespi Aerosphere for COPD – SWOT analysis
Figure 22: The authors drug assessment summary of Bevespi Aerosphere for COPD
Figure 23: The authors drug assessment summary of Bevespi Aerosphere for COPD
Figure 24: Bevespi Aerosphere sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 25: Breo for COPD – SWOT analysis
Figure 26: The authors drug assessment summary of Breo for COPD
Figure 27: The authors drug assessment summary of Breo for COPD
Figure 28: Breo sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 29: Daliresp for COPD – SWOT analysis
Figure 30: The authors drug assessment summary of Daliresp for COPD
Figure 31: The authors drug assessment summary of Daliresp for COPD
Figure 32: Daliresp sales for COPD across the US and major EU markets, by country, 2017–26
Figure 33: Duaklir Pressair for COPD – SWOT analysis
Figure 34: The authors drug assessment summary of Duaklir Pressair for COPD
Figure 35: The authors drug assessment summary of Duaklir Pressair for COPD
Figure 36: Duaklir Pressair sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 37: Incruse for COPD – SWOT analysis
Figure 38: The authors drug assessment summary of Incruse for COPD
Figure 39: The authors drug assessment summary of Incruse for COPD
Figure 40: Incruse sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 41: PT010 for COPD – SWOT analysis
Figure 42: The authors drug assessment summary of PT010 for COPD
Figure 43: The authors drug assessment summary of PT010 for COPD
Figure 44: PT010 sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 45: Seebri for COPD – SWOT analysis
Figure 46: The authors drug assessment summary of Seebri Neohaler for COPD
Figure 47: The authors drug assessment summary of Seebri Neohaler for COPD
Figure 48: Seebri Neohaler sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 49: Spiriva for COPD – SWOT analysis
Figure 50: The authors drug assessment summary of Spiriva for COPD
Figure 51: The authors drug assessment summary of Spiriva for COPD
Figure 52: Spiriva sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 53: Stiolto Respimat for COPD – SWOT analysis
Figure 54: The authors drug assessment summary of Stiolto Respimat for COPD
Figure 55: The authors drug assessment summary of Stiolto Respimat for COPD
Figure 56: Stiolto Respimat sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 57: Striverdi Respimat for COPD – SWOT analysis
Figure 58: The authors drug assessment summary of Striverdi Respimat for COPD
Figure 59: The authors drug assessment summary of Striverdi Respimat for COPD
Figure 60: Striverdi Respimat sales for COPD across the US and five major EU markets, by country, 2017–26
Figure 61: Symbicort for COPD – SWOT analysis
Figure 62: The authors drug assessment summary of Symbicort for COPD
Figure 63: The authors drug assessment summary of Symbicort for COPD
Figure 64: Symbicort sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 65: Trelegy Ellipta for COPD – SWOT analysis
Figure 66: The authors drug assessment summary of Trelegy Ellipta for COPD
Figure 67: The authors drug assessment summary of Trelegy Ellipta for COPD
Figure 68: Trelegy Ellipta sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 69: Trimbow for COPD – SWOT analysis
Figure 70: The authors drug assessment summary of Trimbow for COPD
Figure 71: The authors drug assessment summary of Trimbow for COPD
Figure 72: Trimbow sales for COPD across the five major EU markets, by country, 2017–26
Figure 73: Tudorza Pressair for COPD – SWOT analysis
Figure 74: The authors drug assessment summary of Tudorza Pressair for COPD
Figure 75: The authors drug assessment summary of Tudorza Pressair for COPD
Figure 76: Tudorza Pressair sales for COPD across the US, Japan, and major EU markets, by country, 2017–26
Figure 77: Utibron for COPD – SWOT analysis
Figure 78: The authors drug assessment summary of Ultibro/Utibron for COPD
Figure 79: The authors drug assessment summary of Ultibro/Utibron for COPD
Figure 80: Utibron sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 81: Percentage of COPD patients remaining undiagnosed, by severity and country
Figure 82: Severity of prevalent COPD cases across the US, Japan, and five major EU markets, by region (%)
Figure 83: Type of physician treating COPD, by severity
Figure 84: Top three treatment challenges in COPD
Figure 85: Trends in total prevalent cases of COPD in the US, Japan, and five major EU markets, by country, 2018–38
Figure 86: Advair for COPD – SWOT analysis
Figure 87: The authors drug assessment summary of Advair for COPD
Figure 88: The authors drug assessment summary of Advair for COPD
Figure 89: Advair sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 90: Anoro for COPD – SWOT analysis
Figure 91: The authors drug assessment summary of Anoro for COPD
Figure 92: The authors drug assessment summary of Anoro for COPD
Figure 93: Anoro sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 94: Arcapta for COPD – SWOT analysis
Figure 95: The authors drug assessment summary of Arcapta for COPD
Figure 96: The authors drug assessment summary of Arcapta for COPD
Figure 97: Arcapta Neohaler sales for COPD across Japan and the five major EU markets, by country, 2017–26
Figure 98: Bevespi Aerosphere for COPD – SWOT analysis
Figure 99: The authors drug assessment summary of Bevespi Aerosphere for COPD
Figure 100: The authors drug assessment summary of Bevespi Aerosphere for COPD
Figure 101: Bevespi Aerosphere sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 102: Breo for COPD – SWOT analysis
Figure 103: The authors drug assessment summary of Breo for COPD
Figure 104: The authors drug assessment summary of Breo for COPD
Figure 105: Breo sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 106: Daliresp for COPD – SWOT analysis
Figure 107: The authors drug assessment summary of Daliresp for COPD
Figure 108: The authors drug assessment summary of Daliresp for COPD
Figure 109: Daliresp sales for COPD across the US and major EU markets, by country, 2017–26
Figure 110: Duaklir Pressair for COPD – SWOT analysis
Figure 111: The authors drug assessment summary of Duaklir Pressair for COPD
Figure 112: The authors drug assessment summary of Duaklir Pressair for COPD
Figure 113: Duaklir Pressair sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 114: Incruse for COPD – SWOT analysis
Figure 115: The authors drug assessment summary of Incruse for COPD
Figure 116: The authors drug assessment summary of Incruse for COPD
Figure 117: Incruse sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 118: Seebri for COPD – SWOT analysis
Figure 119: The authors drug assessment summary of Seebri Neohaler for COPD
Figure 120: The authors drug assessment summary of Seebri Neohaler for COPD
Figure 121: Seebri Neohaler sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 122: Spiriva for COPD – SWOT analysis
Figure 123: The authors drug assessment summary of Spiriva for COPD
Figure 124: The authors drug assessment summary of Spiriva for COPD
Figure 125: Spiriva sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 126: Stiolto Respimat for COPD – SWOT analysis
Figure 127: The authors drug assessment summary of Stiolto Respimat for COPD
Figure 128: The authors drug assessment summary of Stiolto Respimat for COPD
Figure 129: Stiolto Respimat sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 130: Striverdi Respimat for COPD – SWOT analysis
Figure 131: The authors drug assessment summary of Striverdi Respimat for COPD
Figure 132: The authors drug assessment summary of Striverdi Respimat for COPD
Figure 133: Striverdi Respimat sales for COPD across the US and five major EU markets, by country, 2017–26
Figure 134: Symbicort for COPD – SWOT analysis
Figure 135: The authors drug assessment summary of Symbicort for COPD
Figure 136: The authors drug assessment summary of Symbicort for COPD
Figure 137: Symbicort sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 138: Trelegy Ellipta for COPD – SWOT analysis
Figure 139: The authors drug assessment summary of Trelegy Ellipta for COPD
Figure 140: The authors drug assessment summary of Trelegy Ellipta for COPD
Figure 141: Trelegy Ellipta sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 142: Trimbow for COPD – SWOT analysis
Figure 143: The authors drug assessment summary of Trimbow for COPD
Figure 144: The authors drug assessment summary of Trimbow for COPD
Figure 145: Trimbow sales for COPD across the five major EU markets, by country, 2017–26
Figure 146: Tudorza Pressair for COPD – SWOT analysis
Figure 147: The authors drug assessment summary of Tudorza Pressair for COPD
Figure 148: The authors drug assessment summary of Tudorza Pressair for COPD
Figure 149: Tudorza Pressair sales for COPD across the US, Japan, and major EU markets, by country, 2017–26
Figure 150: Utibron for COPD – SWOT analysis
Figure 151: The authors drug assessment summary of Ultibro/Utibron for COPD
Figure 152: The authors drug assessment summary of Ultibro/Utibron for COPD
Figure 153: Utibron sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 154: NICE COPD guideline, 2010
Figure 155: The authors drug assessment summary of Nucala for COPD
Figure 156: The authors drug assessment summary of Nucala for COPD
Figure 157: PT010 for COPD – SWOT analysis
Figure 158: The authors drug assessment summary of PT010 for COPD
Figure 159: The authors drug assessment summary of PT010 for COPD
Figure 160: PT010 sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 161: The authors drug assessment summary of revefenacin for COPD
Figure 162: The authors drug assessment summary of revefenacin for COPD
LIST OF TABLES
Table 1: Exchange rates used for calculating prices
Table 2: Pulmonologists and primary care physicians surveyed for the COPD primary research study, 2017
Table 3: Advair drug profile
Table 4: Advair Phase III data in COPD
Table 5: Advair sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 6: Anoro drug profile
Table 7: Anoro Phase III data in COPD
Table 8: Anoro sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 9: Arcapta drug profile
Table 10: Arcapta Phase III data in COPD
Table 11: Arcapta Neohaler sales for COPD across Japan and the five major EU markets, by country ($m), 2017–26
Table 12: Bevespi Aerosphere drug profile
Table 13: Bevespi Aerosphere Phase III data in COPD
Table 14: Other Bevespi Aerosphere Phase III trial data
Table 15: Bevespi Aerosphere ongoing Phase III trial in COPD
Table 16: Bevespi Aerosphere sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 17: Breo drug profile
Table 18: Breo Phase III data in COPD
Table 19: Breo Phase III trials in COPD
Table 20: Breo sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 21: Daliresp drug profile
Table 22: Daliresp Phase III data in COPD
Table 23: Daliresp sales for COPD across the US and major EU markets, by country ($m), 2017–26
Table 24: Duaklir Pressair drug profile
Table 25: Duaklir Pressair Phase III data in COPD
Table 26: Duaklir Pressair Phase III trials in COPD
Table 27: Duaklir Pressair sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 28: Incruse drug profile
Table 29: Incruse Phase III data in COPD
Table 30: Incruse sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 31: PT010 drug profile
Table 32: PT010 Phase III data in COPD
Table 33: PT010 Phase III trials in COPD
Table 34: PT010 sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 35: Seebri Neohaler drug profile
Table 36: Seebri Neohaler Phase III data in COPD
Table 37: Seebri Neohaler US Phase III trial data
Table 38: Seebri Neohaler sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 39: Spiriva drug profile
Table 40: Spiriva HandiHaler Phase III data in COPD
Table 41: Spiriva Respimat Phase III data in COPD
Table 42: Spiriva Respimat’s long-term Phase III TIOSPIR study against Spiriva HandiHaler
Table 43: Spiriva sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 44: Stiolto Respimat drug profile
Table 45: Stiolto Respimat Phase III data in COPD
Table 46: Stiolto Respimat Phase III and Phase IIIb/IV data in COPD
Table 47: Stiolto Respimat’s ongoing Phase IV trial in COPD
Table 48: Stiolto Respimat sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 49: Striverdi Respimat drug profile
Table 50: Striverdi Respimat Phase III data in COPD
Table 51: Striverdi Respimat sales for COPD across the US and five major EU markets, by country ($m), 2017–26
Table 52: Symbicort drug profile
Table 53: Overview of pivotal trial data for Symbicort in COPD
Table 54: Symbicort sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 55: Trelegy Ellipta drug profile
Table 56: Trelegy Ellipta Phase III data in COPD
Table 57: Trelegy Ellipta Phase III trial in COPD
Table 58: Trelegy Ellipta sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 59: Trimbow drug profile
Table 60: Trimbow Phase III data in COPD
Table 61: Trimbow Phase III trial in COPD
Table 62: Trimbow sales for COPD across the five major EU markets, by country ($m), 2017–26
Table 63: Tudorza Pressair drug profile
Table 64: Tudorza Pressair Phase III data in COPD
Table 65: Tudorza Pressair sales for COPD across the US, Japan, and major EU markets, by country ($m), 2017–26
Table 66: Utibron drug profile
Table 67: Utibron Phase III EXPEDITION trial data in COPD
Table 68: Utibron other Phase III data in COPD
Table 69: Utibron sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 70: Pulmonologists and primary care physicians surveyed for the COPD primary research study, 2017
Table 71: Risk factors for COPD that have a role during different stages of life
Table 72: GOLD and LLN classification systems for COPD
Table 73: Key treatments available for COPD across the US, Japan, and five major EU markets
Table 74: GOLD recommendations for initial pharmacological management of COPD
Table 75: Type of physician treating COPD, by severity and country
Table 76: Compliance rates by formulation in the US, Japan, and five major EU markets, by country
Table 77: Factors influencing physician prescribing in COPD, by country (scores out of 100)
Table 78: Relative importance of treatment challenges in COPD, by country
Table 79: Sources used for the epidemiological analysis of COPD in the US, Japan, and five major EU markets, by country
Table 80: Total prevalent cases of COPD in the US, Japan, and five major EU markets, by country, 2018–38
Table 81: Key marketed products for COPD
Table 82: Advair drug profile
Table 83: Advair Phase III data in COPD
Table 84: Advair sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 85: Anoro drug profile
Table 86: Anoro Phase III data in COPD
Table 87: Anoro sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 88: Arcapta drug profile
Table 89: Arcapta Phase III data in COPD
Table 90: Arcapta Neohaler sales for COPD across Japan and the five major EU markets, by country ($m), 2017–26
Table 91: Bevespi Aerosphere drug profile
Table 92: Bevespi Aerosphere Phase III data in COPD
Table 93: Other Bevespi Aerosphere Phase III trial data
Table 94: Bevespi Aerosphere ongoing Phase III trial in COPD
Table 95: Bevespi Aerosphere sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 96: Breo drug profile
Table 97: Breo Phase III data in COPD
Table 98: Breo Phase III trials in COPD
Table 99: Breo sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 100: Daliresp drug profile
Table 101: Daliresp Phase III data in COPD
Table 102: Daliresp sales for COPD across the US and major EU markets, by country ($m), 2017–26
Table 103: Duaklir Pressair drug profile
Table 104: Duaklir Pressair Phase III data in COPD
Table 105: Duaklir Pressair Phase III trials in COPD
Table 106: Duaklir Pressair sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 107: Incruse drug profile
Table 108: Incruse Phase III data in COPD
Table 109: Incruse sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 110: Seebri Neohaler drug profile
Table 111: Seebri Neohaler Phase III data in COPD
Table 112: Seebri Neohaler US Phase III trial data
Table 113: Seebri Neohaler sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 114: Spiriva drug profile
Table 115: Spiriva HandiHaler Phase III data in COPD
Table 116: Spiriva Respimat Phase III data in COPD
Table 117: Spiriva Respimat’s long-term Phase III TIOSPIR study against Spiriva HandiHaler
Table 118: Spiriva sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 119: Stiolto Respimat drug profile
Table 120: Stiolto Respimat Phase III data in COPD
Table 121: Stiolto Respimat Phase III and Phase IIIb/IV data in COPD
Table 122: Stiolto Respimat’s ongoing Phase IV trial in COPD
Table 123: Stiolto Respimat sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 124: Striverdi Respimat drug profile
Table 125: Striverdi Respimat Phase III data in COPD
Table 126: Striverdi Respimat sales for COPD across the US and five major EU markets, by country ($m), 2017–26
Table 127: Symbicort drug profile
Table 128: Overview of pivotal trial data for Symbicort in COPD
Table 129: Symbicort sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 130: Trelegy Ellipta drug profile
Table 131: Trelegy Ellipta Phase III data in COPD
Table 132: Trelegy Ellipta Phase III trial in COPD
Table 133: Trelegy Ellipta sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 134: Trimbow drug profile
Table 135: Trimbow Phase III data in COPD
Table 136: Trimbow Phase III trial in COPD
Table 137: Trimbow sales for COPD across the five major EU markets, by country ($m), 2017–26
Table 138: Tudorza Pressair drug profile
Table 139: Tudorza Pressair Phase III data in COPD
Table 140: Tudorza Pressair sales for COPD across the US, Japan, and major EU markets, by country ($m), 2017–26
Table 141: Utibron drug profile
Table 142: Utibron Phase III EXPEDITION trial data in COPD
Table 143: Utibron other Phase III data in COPD
Table 144: Utibron sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 145: Marketed products and approved indications for COPD in the US, Japan, and five major EU markets
Table 146: Late-stage candidates in development for COPD
Table 147: US pricing of key marketed drugs
Table 148: Asthma and COPD spend by payers, 2014
Table 149: Top 10 asthma and COPD drug spend by Express Scripts members
Table 150: Spend on the top three asthma and COPD drugs by Medicare Part D beneficiaries, 2013
Table 151: COPD GOLD patient categorization and recommended treatments, 2015
Table 152: GOLD airflow limitation risk groups
Table 153: Formulary placement of COPD drugs in selected commercial formularies
Table 154: Formulary placement of COPD drugs in the top five 2015 Medicare Part D formularies
Table 155: Formulary placement of COPD drugs in selected large Medicaid states’ preferred drug lists
Table 156: Express Scripts’ TRICARE formulary placement of COPD drugs
Table 157: CVS Caremark’s and Express Scripts’ formulary-excluded COPD drugs
Table 158: Prior authorization criteria for COPD drugs by major health insurers and pharmacy benefit managers
Table 159: Japan – pricing premiums given to medicines that can demonstrate benefit over comparators
Table 160: Price calculation methodologies for COPD drugs in Japan launched after 2008
Table 161: Pricing of key marketed COPD drugs in Japan
Table 162: Annual treatment cost of COPD drugs in the five major EU markets
Table 163: Access controls for COPD medications in the five major EU markets
Table 164: Availability and substitutability of branded generic inhalers in the five major EU markets
Table 165: List price differential between branded ICS/LABAs and branded generics for COPD in the five major EU markets
Table 166: Market access levers impacting ICS/LABA generic inhaler uptake in the five major EU markets
Table 167: Transparency Committee’s ASMR ratings and pricing implications
Table 168: Transparency Committee's SMR ratings and pricing implications
Table 169: Transparency Committee's assessment of COPD treatments
Table 170: G-BA assessment of key COPD therapies
Table 171: Reimbursement conditions for COPD treatments in Italy
Table 172: Italy local formulary decisions for COPD drugs
Table 173: Therapeutic positioning reports for COPD drugs in Spain
Table 174: Spain regional assessments of COPD drugs
Table 175: NICE assessments of key COPD therapies
Table 176: CCG formulary inclusions for key COPD drugs
Table 177: SMC decisions on key COPD therapies
Table 178: Price sources and calculations for the US
Table 179: Price sources and calculations for the EU
Table 180: Exchange rates used for calculating branded drug prices
Table 181: Profiled pipeline products in development for COPD
Table 182: Nucala drug profile
Table 183: Nucala Phase III data in COPD
Table 184: PT010 drug profile
Table 185: PT010 Phase III data in COPD
Table 186: PT010 Phase III trials in COPD
Table 187: PT010 sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 188: Revefenacin drug profile
Table 189: Revefenacin Phase III data in COPD
Table 190: Revefenacin Phase III trial in COPD
Overview
Recent Forecast Updates
Market Dynamics
Forecast And Future Trends
Market Definition And Methodology
Primary Research Methodology
Bibliography
Product Profile: Advair
Product Profile: Anoro Ellipta
Product Profile: Arcapta Neohaler
Product Profile: Bevespi Aerosphere
Product Profile: Breo Ellipta
Product Profile: Daliresp
Product Profile: Duaklir Pressair
Product Profile: Incruse Ellipta
Product Profile (Late Stage): Pt010
Product Profile: Seebri Neohaler
Product Profile: Spiriva
Product Profile: Stiolto Respimat
Product Profile: Striverdi Respimat
Product Profile: Symbicort
Product Profile: Trelegy Ellipta
Product Profile: Trimbow
Product Profile: Tudorza Pressair
Product Profile: Utibron Neohaler
TREATMENT: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (Published on 31 July 2018)
Overview
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends
Unmet Needs In Chronic Obstructive Pulmonary Disease
Pipeline Drugs And Future Treatment
EPIDEMIOLOGY: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (Published on 22 January 2019)
Overview
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources
MARKETED DRUGS: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (Published on 31 July 2018)
Overview
Product Overview
Product Profile: Advair
Product Profile: Anoro Ellipta
Product Profile: Arcapta Neohaler
Product Profile: Bevespi Aerosphere
Product Profile: Breo Ellipta
Product Profile: Daliresp
Product Profile: Duaklir Pressair
Product Profile: Incruse Ellipta
Product Profile: Seebri Neohaler
Product Profile: Spiriva
Product Profile: Stiolto Respimat
Product Profile: Striverdi Respimat
Product Profile: Symbicort
Product Profile: Trelegy Ellipta
Product Profile: Trimbow
Product Profile: Tudorza Pressair
Product Profile: Utibron Neohaler
COPD PRICING, REIMBURSEMENT, AND ACCESS (Published on 11 May 2016)
Overview
Executive Summary
Market Context
Global Payer And Key Opinion Leader Insights
Us Pricing
Us Payer Insights
Us Reimbursement
Japan
Five Major Eu Markets Pricing
Five Major Eu Markets Payer Insights
Generic Ics/Laba Inhalers In The Five Major Eu Markets
France
Germany
Italy
Spain
Uk
Methodology
PIPELINE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (Published on 31 July 2018)
Overview
Clinical Pipeline Overview
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Nucala
Product Profile (Late Stage): Pt010
Product Profile (Late Stage): Revefenacin
LIST OF FIGURES
Figure 1: COPD – current and future market dynamics analysis
Figure 2: The authors assessment summary of key marketed and pipeline drugs for COPD
Figure 3: COPD sales across the US, Japan, and five major EU markets, by country, 2017–26
Figure 4: Sales of Anoro Ellipta, Bevespi Aerosphere, Duaklir Pressair, Stiolto Respimat, and Utibron Neohaler across the US, Japan, and five major EU markets, 2017–26
Figure 5: Sales of Trelegy Ellipta, Trimbow, and PT010 across the US, Japan, and five major EU markets, 2017–26
Figure 6: Sales of the ICS/LABA class across the US, Japan, and five major EU markets, by product, 2017–26
Figure 7: Patient-based forecast methodology for COPD
Figure 8: Price sources and calculations, by country
Figure 9: Advair for COPD – SWOT analysis
Figure 10: The authors drug assessment summary of Advair for COPD
Figure 11: The authors drug assessment summary of Advair for COPD
Figure 12: Advair sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 13: Anoro for COPD – SWOT analysis
Figure 14: The authors drug assessment summary of Anoro for COPD
Figure 15: The authors drug assessment summary of Anoro for COPD
Figure 16: Anoro sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 17: Arcapta for COPD – SWOT analysis
Figure 18: The authors drug assessment summary of Arcapta for COPD
Figure 19: The authors drug assessment summary of Arcapta for COPD
Figure 20: Arcapta Neohaler sales for COPD across Japan and the five major EU markets, by country, 2017–26
Figure 21: Bevespi Aerosphere for COPD – SWOT analysis
Figure 22: The authors drug assessment summary of Bevespi Aerosphere for COPD
Figure 23: The authors drug assessment summary of Bevespi Aerosphere for COPD
Figure 24: Bevespi Aerosphere sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 25: Breo for COPD – SWOT analysis
Figure 26: The authors drug assessment summary of Breo for COPD
Figure 27: The authors drug assessment summary of Breo for COPD
Figure 28: Breo sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 29: Daliresp for COPD – SWOT analysis
Figure 30: The authors drug assessment summary of Daliresp for COPD
Figure 31: The authors drug assessment summary of Daliresp for COPD
Figure 32: Daliresp sales for COPD across the US and major EU markets, by country, 2017–26
Figure 33: Duaklir Pressair for COPD – SWOT analysis
Figure 34: The authors drug assessment summary of Duaklir Pressair for COPD
Figure 35: The authors drug assessment summary of Duaklir Pressair for COPD
Figure 36: Duaklir Pressair sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 37: Incruse for COPD – SWOT analysis
Figure 38: The authors drug assessment summary of Incruse for COPD
Figure 39: The authors drug assessment summary of Incruse for COPD
Figure 40: Incruse sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 41: PT010 for COPD – SWOT analysis
Figure 42: The authors drug assessment summary of PT010 for COPD
Figure 43: The authors drug assessment summary of PT010 for COPD
Figure 44: PT010 sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 45: Seebri for COPD – SWOT analysis
Figure 46: The authors drug assessment summary of Seebri Neohaler for COPD
Figure 47: The authors drug assessment summary of Seebri Neohaler for COPD
Figure 48: Seebri Neohaler sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 49: Spiriva for COPD – SWOT analysis
Figure 50: The authors drug assessment summary of Spiriva for COPD
Figure 51: The authors drug assessment summary of Spiriva for COPD
Figure 52: Spiriva sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 53: Stiolto Respimat for COPD – SWOT analysis
Figure 54: The authors drug assessment summary of Stiolto Respimat for COPD
Figure 55: The authors drug assessment summary of Stiolto Respimat for COPD
Figure 56: Stiolto Respimat sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 57: Striverdi Respimat for COPD – SWOT analysis
Figure 58: The authors drug assessment summary of Striverdi Respimat for COPD
Figure 59: The authors drug assessment summary of Striverdi Respimat for COPD
Figure 60: Striverdi Respimat sales for COPD across the US and five major EU markets, by country, 2017–26
Figure 61: Symbicort for COPD – SWOT analysis
Figure 62: The authors drug assessment summary of Symbicort for COPD
Figure 63: The authors drug assessment summary of Symbicort for COPD
Figure 64: Symbicort sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 65: Trelegy Ellipta for COPD – SWOT analysis
Figure 66: The authors drug assessment summary of Trelegy Ellipta for COPD
Figure 67: The authors drug assessment summary of Trelegy Ellipta for COPD
Figure 68: Trelegy Ellipta sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 69: Trimbow for COPD – SWOT analysis
Figure 70: The authors drug assessment summary of Trimbow for COPD
Figure 71: The authors drug assessment summary of Trimbow for COPD
Figure 72: Trimbow sales for COPD across the five major EU markets, by country, 2017–26
Figure 73: Tudorza Pressair for COPD – SWOT analysis
Figure 74: The authors drug assessment summary of Tudorza Pressair for COPD
Figure 75: The authors drug assessment summary of Tudorza Pressair for COPD
Figure 76: Tudorza Pressair sales for COPD across the US, Japan, and major EU markets, by country, 2017–26
Figure 77: Utibron for COPD – SWOT analysis
Figure 78: The authors drug assessment summary of Ultibro/Utibron for COPD
Figure 79: The authors drug assessment summary of Ultibro/Utibron for COPD
Figure 80: Utibron sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 81: Percentage of COPD patients remaining undiagnosed, by severity and country
Figure 82: Severity of prevalent COPD cases across the US, Japan, and five major EU markets, by region (%)
Figure 83: Type of physician treating COPD, by severity
Figure 84: Top three treatment challenges in COPD
Figure 85: Trends in total prevalent cases of COPD in the US, Japan, and five major EU markets, by country, 2018–38
Figure 86: Advair for COPD – SWOT analysis
Figure 87: The authors drug assessment summary of Advair for COPD
Figure 88: The authors drug assessment summary of Advair for COPD
Figure 89: Advair sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 90: Anoro for COPD – SWOT analysis
Figure 91: The authors drug assessment summary of Anoro for COPD
Figure 92: The authors drug assessment summary of Anoro for COPD
Figure 93: Anoro sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 94: Arcapta for COPD – SWOT analysis
Figure 95: The authors drug assessment summary of Arcapta for COPD
Figure 96: The authors drug assessment summary of Arcapta for COPD
Figure 97: Arcapta Neohaler sales for COPD across Japan and the five major EU markets, by country, 2017–26
Figure 98: Bevespi Aerosphere for COPD – SWOT analysis
Figure 99: The authors drug assessment summary of Bevespi Aerosphere for COPD
Figure 100: The authors drug assessment summary of Bevespi Aerosphere for COPD
Figure 101: Bevespi Aerosphere sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 102: Breo for COPD – SWOT analysis
Figure 103: The authors drug assessment summary of Breo for COPD
Figure 104: The authors drug assessment summary of Breo for COPD
Figure 105: Breo sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 106: Daliresp for COPD – SWOT analysis
Figure 107: The authors drug assessment summary of Daliresp for COPD
Figure 108: The authors drug assessment summary of Daliresp for COPD
Figure 109: Daliresp sales for COPD across the US and major EU markets, by country, 2017–26
Figure 110: Duaklir Pressair for COPD – SWOT analysis
Figure 111: The authors drug assessment summary of Duaklir Pressair for COPD
Figure 112: The authors drug assessment summary of Duaklir Pressair for COPD
Figure 113: Duaklir Pressair sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 114: Incruse for COPD – SWOT analysis
Figure 115: The authors drug assessment summary of Incruse for COPD
Figure 116: The authors drug assessment summary of Incruse for COPD
Figure 117: Incruse sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 118: Seebri for COPD – SWOT analysis
Figure 119: The authors drug assessment summary of Seebri Neohaler for COPD
Figure 120: The authors drug assessment summary of Seebri Neohaler for COPD
Figure 121: Seebri Neohaler sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 122: Spiriva for COPD – SWOT analysis
Figure 123: The authors drug assessment summary of Spiriva for COPD
Figure 124: The authors drug assessment summary of Spiriva for COPD
Figure 125: Spiriva sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 126: Stiolto Respimat for COPD – SWOT analysis
Figure 127: The authors drug assessment summary of Stiolto Respimat for COPD
Figure 128: The authors drug assessment summary of Stiolto Respimat for COPD
Figure 129: Stiolto Respimat sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 130: Striverdi Respimat for COPD – SWOT analysis
Figure 131: The authors drug assessment summary of Striverdi Respimat for COPD
Figure 132: The authors drug assessment summary of Striverdi Respimat for COPD
Figure 133: Striverdi Respimat sales for COPD across the US and five major EU markets, by country, 2017–26
Figure 134: Symbicort for COPD – SWOT analysis
Figure 135: The authors drug assessment summary of Symbicort for COPD
Figure 136: The authors drug assessment summary of Symbicort for COPD
Figure 137: Symbicort sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 138: Trelegy Ellipta for COPD – SWOT analysis
Figure 139: The authors drug assessment summary of Trelegy Ellipta for COPD
Figure 140: The authors drug assessment summary of Trelegy Ellipta for COPD
Figure 141: Trelegy Ellipta sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 142: Trimbow for COPD – SWOT analysis
Figure 143: The authors drug assessment summary of Trimbow for COPD
Figure 144: The authors drug assessment summary of Trimbow for COPD
Figure 145: Trimbow sales for COPD across the five major EU markets, by country, 2017–26
Figure 146: Tudorza Pressair for COPD – SWOT analysis
Figure 147: The authors drug assessment summary of Tudorza Pressair for COPD
Figure 148: The authors drug assessment summary of Tudorza Pressair for COPD
Figure 149: Tudorza Pressair sales for COPD across the US, Japan, and major EU markets, by country, 2017–26
Figure 150: Utibron for COPD – SWOT analysis
Figure 151: The authors drug assessment summary of Ultibro/Utibron for COPD
Figure 152: The authors drug assessment summary of Ultibro/Utibron for COPD
Figure 153: Utibron sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 154: NICE COPD guideline, 2010
Figure 155: The authors drug assessment summary of Nucala for COPD
Figure 156: The authors drug assessment summary of Nucala for COPD
Figure 157: PT010 for COPD – SWOT analysis
Figure 158: The authors drug assessment summary of PT010 for COPD
Figure 159: The authors drug assessment summary of PT010 for COPD
Figure 160: PT010 sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 161: The authors drug assessment summary of revefenacin for COPD
Figure 162: The authors drug assessment summary of revefenacin for COPD
LIST OF TABLES
Table 1: Exchange rates used for calculating prices
Table 2: Pulmonologists and primary care physicians surveyed for the COPD primary research study, 2017
Table 3: Advair drug profile
Table 4: Advair Phase III data in COPD
Table 5: Advair sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 6: Anoro drug profile
Table 7: Anoro Phase III data in COPD
Table 8: Anoro sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 9: Arcapta drug profile
Table 10: Arcapta Phase III data in COPD
Table 11: Arcapta Neohaler sales for COPD across Japan and the five major EU markets, by country ($m), 2017–26
Table 12: Bevespi Aerosphere drug profile
Table 13: Bevespi Aerosphere Phase III data in COPD
Table 14: Other Bevespi Aerosphere Phase III trial data
Table 15: Bevespi Aerosphere ongoing Phase III trial in COPD
Table 16: Bevespi Aerosphere sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 17: Breo drug profile
Table 18: Breo Phase III data in COPD
Table 19: Breo Phase III trials in COPD
Table 20: Breo sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 21: Daliresp drug profile
Table 22: Daliresp Phase III data in COPD
Table 23: Daliresp sales for COPD across the US and major EU markets, by country ($m), 2017–26
Table 24: Duaklir Pressair drug profile
Table 25: Duaklir Pressair Phase III data in COPD
Table 26: Duaklir Pressair Phase III trials in COPD
Table 27: Duaklir Pressair sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 28: Incruse drug profile
Table 29: Incruse Phase III data in COPD
Table 30: Incruse sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 31: PT010 drug profile
Table 32: PT010 Phase III data in COPD
Table 33: PT010 Phase III trials in COPD
Table 34: PT010 sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 35: Seebri Neohaler drug profile
Table 36: Seebri Neohaler Phase III data in COPD
Table 37: Seebri Neohaler US Phase III trial data
Table 38: Seebri Neohaler sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 39: Spiriva drug profile
Table 40: Spiriva HandiHaler Phase III data in COPD
Table 41: Spiriva Respimat Phase III data in COPD
Table 42: Spiriva Respimat’s long-term Phase III TIOSPIR study against Spiriva HandiHaler
Table 43: Spiriva sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 44: Stiolto Respimat drug profile
Table 45: Stiolto Respimat Phase III data in COPD
Table 46: Stiolto Respimat Phase III and Phase IIIb/IV data in COPD
Table 47: Stiolto Respimat’s ongoing Phase IV trial in COPD
Table 48: Stiolto Respimat sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 49: Striverdi Respimat drug profile
Table 50: Striverdi Respimat Phase III data in COPD
Table 51: Striverdi Respimat sales for COPD across the US and five major EU markets, by country ($m), 2017–26
Table 52: Symbicort drug profile
Table 53: Overview of pivotal trial data for Symbicort in COPD
Table 54: Symbicort sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 55: Trelegy Ellipta drug profile
Table 56: Trelegy Ellipta Phase III data in COPD
Table 57: Trelegy Ellipta Phase III trial in COPD
Table 58: Trelegy Ellipta sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 59: Trimbow drug profile
Table 60: Trimbow Phase III data in COPD
Table 61: Trimbow Phase III trial in COPD
Table 62: Trimbow sales for COPD across the five major EU markets, by country ($m), 2017–26
Table 63: Tudorza Pressair drug profile
Table 64: Tudorza Pressair Phase III data in COPD
Table 65: Tudorza Pressair sales for COPD across the US, Japan, and major EU markets, by country ($m), 2017–26
Table 66: Utibron drug profile
Table 67: Utibron Phase III EXPEDITION trial data in COPD
Table 68: Utibron other Phase III data in COPD
Table 69: Utibron sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 70: Pulmonologists and primary care physicians surveyed for the COPD primary research study, 2017
Table 71: Risk factors for COPD that have a role during different stages of life
Table 72: GOLD and LLN classification systems for COPD
Table 73: Key treatments available for COPD across the US, Japan, and five major EU markets
Table 74: GOLD recommendations for initial pharmacological management of COPD
Table 75: Type of physician treating COPD, by severity and country
Table 76: Compliance rates by formulation in the US, Japan, and five major EU markets, by country
Table 77: Factors influencing physician prescribing in COPD, by country (scores out of 100)
Table 78: Relative importance of treatment challenges in COPD, by country
Table 79: Sources used for the epidemiological analysis of COPD in the US, Japan, and five major EU markets, by country
Table 80: Total prevalent cases of COPD in the US, Japan, and five major EU markets, by country, 2018–38
Table 81: Key marketed products for COPD
Table 82: Advair drug profile
Table 83: Advair Phase III data in COPD
Table 84: Advair sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 85: Anoro drug profile
Table 86: Anoro Phase III data in COPD
Table 87: Anoro sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 88: Arcapta drug profile
Table 89: Arcapta Phase III data in COPD
Table 90: Arcapta Neohaler sales for COPD across Japan and the five major EU markets, by country ($m), 2017–26
Table 91: Bevespi Aerosphere drug profile
Table 92: Bevespi Aerosphere Phase III data in COPD
Table 93: Other Bevespi Aerosphere Phase III trial data
Table 94: Bevespi Aerosphere ongoing Phase III trial in COPD
Table 95: Bevespi Aerosphere sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 96: Breo drug profile
Table 97: Breo Phase III data in COPD
Table 98: Breo Phase III trials in COPD
Table 99: Breo sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 100: Daliresp drug profile
Table 101: Daliresp Phase III data in COPD
Table 102: Daliresp sales for COPD across the US and major EU markets, by country ($m), 2017–26
Table 103: Duaklir Pressair drug profile
Table 104: Duaklir Pressair Phase III data in COPD
Table 105: Duaklir Pressair Phase III trials in COPD
Table 106: Duaklir Pressair sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 107: Incruse drug profile
Table 108: Incruse Phase III data in COPD
Table 109: Incruse sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 110: Seebri Neohaler drug profile
Table 111: Seebri Neohaler Phase III data in COPD
Table 112: Seebri Neohaler US Phase III trial data
Table 113: Seebri Neohaler sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 114: Spiriva drug profile
Table 115: Spiriva HandiHaler Phase III data in COPD
Table 116: Spiriva Respimat Phase III data in COPD
Table 117: Spiriva Respimat’s long-term Phase III TIOSPIR study against Spiriva HandiHaler
Table 118: Spiriva sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 119: Stiolto Respimat drug profile
Table 120: Stiolto Respimat Phase III data in COPD
Table 121: Stiolto Respimat Phase III and Phase IIIb/IV data in COPD
Table 122: Stiolto Respimat’s ongoing Phase IV trial in COPD
Table 123: Stiolto Respimat sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 124: Striverdi Respimat drug profile
Table 125: Striverdi Respimat Phase III data in COPD
Table 126: Striverdi Respimat sales for COPD across the US and five major EU markets, by country ($m), 2017–26
Table 127: Symbicort drug profile
Table 128: Overview of pivotal trial data for Symbicort in COPD
Table 129: Symbicort sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 130: Trelegy Ellipta drug profile
Table 131: Trelegy Ellipta Phase III data in COPD
Table 132: Trelegy Ellipta Phase III trial in COPD
Table 133: Trelegy Ellipta sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 134: Trimbow drug profile
Table 135: Trimbow Phase III data in COPD
Table 136: Trimbow Phase III trial in COPD
Table 137: Trimbow sales for COPD across the five major EU markets, by country ($m), 2017–26
Table 138: Tudorza Pressair drug profile
Table 139: Tudorza Pressair Phase III data in COPD
Table 140: Tudorza Pressair sales for COPD across the US, Japan, and major EU markets, by country ($m), 2017–26
Table 141: Utibron drug profile
Table 142: Utibron Phase III EXPEDITION trial data in COPD
Table 143: Utibron other Phase III data in COPD
Table 144: Utibron sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 145: Marketed products and approved indications for COPD in the US, Japan, and five major EU markets
Table 146: Late-stage candidates in development for COPD
Table 147: US pricing of key marketed drugs
Table 148: Asthma and COPD spend by payers, 2014
Table 149: Top 10 asthma and COPD drug spend by Express Scripts members
Table 150: Spend on the top three asthma and COPD drugs by Medicare Part D beneficiaries, 2013
Table 151: COPD GOLD patient categorization and recommended treatments, 2015
Table 152: GOLD airflow limitation risk groups
Table 153: Formulary placement of COPD drugs in selected commercial formularies
Table 154: Formulary placement of COPD drugs in the top five 2015 Medicare Part D formularies
Table 155: Formulary placement of COPD drugs in selected large Medicaid states’ preferred drug lists
Table 156: Express Scripts’ TRICARE formulary placement of COPD drugs
Table 157: CVS Caremark’s and Express Scripts’ formulary-excluded COPD drugs
Table 158: Prior authorization criteria for COPD drugs by major health insurers and pharmacy benefit managers
Table 159: Japan – pricing premiums given to medicines that can demonstrate benefit over comparators
Table 160: Price calculation methodologies for COPD drugs in Japan launched after 2008
Table 161: Pricing of key marketed COPD drugs in Japan
Table 162: Annual treatment cost of COPD drugs in the five major EU markets
Table 163: Access controls for COPD medications in the five major EU markets
Table 164: Availability and substitutability of branded generic inhalers in the five major EU markets
Table 165: List price differential between branded ICS/LABAs and branded generics for COPD in the five major EU markets
Table 166: Market access levers impacting ICS/LABA generic inhaler uptake in the five major EU markets
Table 167: Transparency Committee’s ASMR ratings and pricing implications
Table 168: Transparency Committee's SMR ratings and pricing implications
Table 169: Transparency Committee's assessment of COPD treatments
Table 170: G-BA assessment of key COPD therapies
Table 171: Reimbursement conditions for COPD treatments in Italy
Table 172: Italy local formulary decisions for COPD drugs
Table 173: Therapeutic positioning reports for COPD drugs in Spain
Table 174: Spain regional assessments of COPD drugs
Table 175: NICE assessments of key COPD therapies
Table 176: CCG formulary inclusions for key COPD drugs
Table 177: SMC decisions on key COPD therapies
Table 178: Price sources and calculations for the US
Table 179: Price sources and calculations for the EU
Table 180: Exchange rates used for calculating branded drug prices
Table 181: Profiled pipeline products in development for COPD
Table 182: Nucala drug profile
Table 183: Nucala Phase III data in COPD
Table 184: PT010 drug profile
Table 185: PT010 Phase III data in COPD
Table 186: PT010 Phase III trials in COPD
Table 187: PT010 sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 188: Revefenacin drug profile
Table 189: Revefenacin Phase III data in COPD
Table 190: Revefenacin Phase III trial in COPD
Note: Product cover images may vary from those shown
3 of 2
LOADING...
